Jaguar Health, Inc. (JAGX) income statement
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.38−0.01 (-2.56%)
Close on Nov 17, 2026Market cap $1.96MP/E –Yield –
Jaguar Health, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 82.3%
- Operating margin
- -93.1%
- Net margin
- -192.6%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 0.69
- Debt to equity
- –
- Debt to assets
- 5.0%
- Cash to current liabilities
- 14.9%
Valuation
- P/E ratio
- –
- Price to sales
- 0.07
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?